Table 3.

Treatment-related adverse events

Treatment-Related Adverse Event, n (%)	Navarixin 30 mg + Pembrolizumab 200 mg n = 51		Navarixin 100 mg + Pembrolizumab 200 mg n = 54
Any grade	37 (73)		33 (61)
Grade 3−5	13 (25)		12 (22)
Led to discontinuation of study drug(s)	3 (6)		4 (7)
Led to death	1 (2)		0

	Any Grade	Grade 3–5	Any Grade	Grade 3–5
Most common (≥2 patients in either treatment arm)a
Neutrophil count decreased	7 (14)	5 (10)	9 (17)	4 (7)
Neutropenia	5 (10)	1 (2)	9 (17)	6 (11)
Fatigue	7 (14)	0	5 (9)	0
Pruritus	6 (12)	0	6 (11)	0
Cough	3 (6)	1 (2)	3 (6)	0
White blood cell count decreased	3 (6)	1 (2)	3 (6)	1 (2)
Pyrexia	2 (4)	0	3 (6)	0
Hypothyroidism	2 (4)	0	2 (4)	0
Nausea	1 (2)	0	3 (6)	0
Vomiting	1 (2)	0	3 (6)	0
Decreased appetite	3 (6)	1 (2)	0	0
Hyperthyroidism	2 (4)	0	1 (2)	0
Rash maculo-papular	2 (4)	0	1 (2)	0
Chills	0	0	2 (4)	0
Diarrhea	0	0	2 (4)	0
Rash	0	0	2 (4)	0

^aAmong treatment-related adverse events of any grade, pneumonitis was reported in 1 patient in each treatment arm and colitis was reported in 1 patient in the navarixin 30-mg arm; neutropenic fever was not reported as a treatment-related adverse event in either treatment arm